GILD Archives - Page 22 of 29

1 minute read

Gilead’s Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate

December 9, 10:42 AM

Kite, a Gilead Sciences Inc company (NASDAQ:GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc’s (NASDAQ:ACLX) lead late-stage product candidate, CART-ddBCMA,…

ACLX

1 minute read

ImmunoGen Announces Clinical Collaboration With Gilead To Evaluate Pivekimab Sunirine In Combination With Magrolimab In Relapsed/Refractory Acute Myeloid Leukemia

By Benzinga Newsdesk

December 9, 7:30 AM

Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of

GILD

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

December 1, 2:33 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

BDX

8 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

December 1, 1:10 PM

During Thursday's session, 108 stocks hit new 52-week highs.

ABC

1 minute read

Analyst Ratings

Expert Ratings for Gilead Sciences

By Benzinga Insights

December 1, 1:04 PM

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

GILD

1 minute read

Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $81

By Benzinga Newsdesk

December 1, 9:51 AM

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $68 to $81.

GILD

1 minute read

Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures

By Vandana Singh

November 28, 12:18 PM

Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences (NASDAQ:RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients…

GILD

2 minute read

What Does Gilead Sciences’ Debt Look Like?

By Benzinga Insights

November 28, 11:23 AM

Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 34.80%. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.

GILD

4 minute read

Gilead And Arcus Biosciences Announce Positive Update On Joint TIGIT Program From Interim Analysis of ARC-7 Study In Non-Small Cell Lung Cancer; Shares Spike Higher

By Benzinga Newsdesk

November 28, 9:32 AM

– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy

GILD

1 minute read

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today

By Benzinga Insights

November 23, 12:03 PM

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 8.0% on an annualized basis…

GILD

Feed Symbols: GILD